NUR 210/ NUR210 Exam 1 – Principles of
Pharmacology Guide ACTUAL EXAM
2026/2027 | Principles of Pharmacology
Guide | Verified Q&A | Pass Guaranteed -
A+ Graded
ART A – MULTIPLE CHOICE (Q1–60)
P
Q1 (Pharmacokinetics – first-pass effect):
A nurse is teaching a patient about why oral morphine requires a higher dose than intravenous
morphine. Which statement by the nurse best explains the first-pass effect?
A) "The liver metabolizes a portion of the drug before it reaches systemic circulation."
B) "The kidneys filter out most of the drug before it can act on receptors in the brain."
C) "The stomach acid destroys approximately 50% of the drug before absorption occurs."
D) "The blood-brain barrier prevents oral drugs from entering the central nervous system."
[CORRECT] A
Rationale: The first-pass effect refers to hepatic metabolism of a drug after absorption from the
GI tract but before reaching systemic circulation, which significantly reduces bioavailability of
orally administered drugs like morphine. Option B is incorrect because renal filtration occurs
after systemic circulation, not before. Option C is incorrect because stomach acid does not
destroy 50% of morphine; the liver is responsible for first-pass metabolism. Option D is incorrect
because the blood-brain barrier affects CNS entry after systemic circulation, not oral
bioavailability.
Q2 (Pharmacokinetics – factors affecting absorption):
A patient with chronic heart failure is prescribed furosemide. The nurse knows that which factor
will most likely DECREASE the rate of oral drug absorption in this patient?
A) Increased gastric motility
B) Decreased splanchnic blood flow
C) Increased surface area of the small intestine
D) Alkaline urine pH
[CORRECT] B
Rationale: In heart failure, decreased cardiac output reduces splanchnic (intestinal) blood flow,
which slows the rate of drug absorption from the GI tract because less blood is available to carry
absorbed drug into systemic circulation. Option A is incorrect because increased gastric motility
would actually decrease absorption time, not decrease the rate. Option C is incorrect because
increased surface area enhances, not decreases, absorption. Option D is incorrect because
urine pH affects renal elimination, not GI absorption.
, 3 (Pharmacokinetics – protein binding):
Q
A 78-year-old patient with low serum albumin is prescribed warfarin. The nurse should monitor
closely for which potential effect?
A) Decreased drug efficacy due to reduced plasma concentration
B) Increased risk of bleeding due to higher free (unbound) drug concentration
C) Increased protein binding causing drug accumulation in tissues
D) Decreased volume of distribution leading to subtherapeutic levels
[CORRECT] B
Rationale: Warfarin is highly protein-bound (approximately 99%); when albumin is low, less drug
is bound to protein, leaving more free (unbound, pharmacologically active) drug available to
exert anticoagulant effects and increasing bleeding risk. Option A is incorrect because free drug
concentration increases, not decreases. Option C is incorrect because low albumin decreases,
not increases, protein binding. Option D is incorrect because volume of distribution is not the
primary concern; the concern is increased free fraction and toxicity.
Q4 (Pharmacokinetics – half-life):
A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A) 6 hours
B) 12 hours
C) 24 hours
D) 30 hours
[CORRECT] D
Rationale: Steady-state concentration is typically reached after approximately 5 half-lives; with a
6-hour half-life, 5 × 6 = 30 hours. Option A represents one half-life (50% of steady state). Option
B represents two half-lives (75% of steady state). Option C represents four half-lives (94% of
steady state). Clinical practice accepts 5 half-lives as the time to reach steady state.
Q5 (Pharmacokinetics – CYP450):
The nurse is reviewing a patient's medication list and notes that the patient takes simvastatin
and recently started taking clarithromycin. What is the nurse's primary concern?
A) Clarithromycin inhibits CYP3A4, increasing simvastatin levels and risk of rhabdomyolysis
B) Clarithromycin induces CYP3A4, decreasing simvastatin effectiveness
C) Simvastatin inhibits clarithromycin metabolism, causing antibiotic toxicity
D) The combination causes additive hypotension
[CORRECT] A
Rationale: Clarithromycin is a potent CYP3A4 inhibitor; simvastatin is a CYP3A4 substrate.
Inhibition increases simvastatin plasma levels, raising the risk of myopathy and rhabdomyolysis,
a potentially fatal muscle breakdown. Option B is incorrect because clarithromycin inhibits, not
induces, CYP3A4. Option C is incorrect because simvastatin does not inhibit clarithromycin
metabolism. Option D is incorrect because neither drug significantly affects blood pressure.
Q6 (Pharmacokinetics – renal elimination):
A patient with chronic kidney disease (GFR 25 mL/min) is prescribed a drug that is 90%
eliminated unchanged by the kidneys. What is the nurse's priority action?
A) Administer the drug with food to enhance absorption
B) Recommend an increased dose to compensate for reduced elimination
, ) Notify the prescriber to discuss dose reduction or extended dosing interval
C
D) Monitor liver function tests because renal impairment increases hepatic metabolism
[CORRECT] C
Rationale: For drugs primarily eliminated by the kidneys, significantly reduced GFR (normal >90
mL/min) causes drug accumulation and toxicity; the nurse must notify the prescriber to adjust
the dose or extend the dosing interval based on renal function. Option A is incorrect because
absorption is not the issue; elimination is. Option B is incorrect because increasing the dose
would worsen accumulation and toxicity. Option D is incorrect because while some hepatic
compensation may occur, it is insufficient to prevent toxicity of a 90% renally eliminated drug.
Q7 (Pharmacokinetics – volume of distribution):
A drug has a very large volume of distribution (Vd > 200 L). What does this indicate to the
nurse?
A) The drug is highly concentrated in the plasma and will have a short duration of action.
B) The drug is extensively distributed into tissues and may have a prolonged effect.
C) The drug is rapidly metabolized by the liver and requires frequent dosing.
D) The drug is poorly absorbed from the gastrointestinal tract.
[CORRECT] B
Rationale: A large volume of distribution indicates extensive tissue distribution beyond plasma
volume (which is approximately 3 L for a 70 kg adult); drugs with large Vd (e.g., digoxin,
antidepressants) sequester in tissues and may have prolonged effects and half-lives. Option A
is incorrect because large Vd means low plasma concentration, not high. Option C is incorrect
because metabolism rate is independent of Vd. Option D is incorrect because absorption and
distribution are separate pharmacokinetic processes.
Q8 (Pharmacokinetics – blood-brain barrier):
Which characteristic allows a drug to most easily cross the blood-brain barrier?
A) High molecular weight and hydrophilic properties
B) Low lipid solubility and protein binding
C) Small molecular size and high lipid solubility
D) High degree of ionization at physiological pH
[CORRECT] C
Rationale: The blood-brain barrier consists of tight endothelial junctions that restrict passage of
large, polar, or ionized molecules; small, lipid-soluble (lipophilic), non-ionized drugs cross most
easily by passive diffusion. Option A is incorrect because large, hydrophilic molecules cannot
cross. Option B is incorrect because low lipid solubility prevents barrier penetration. Option D is
incorrect because ionized forms are water-soluble and cannot cross lipid membranes.
Q9 (Pharmacodynamics – agonist vs. antagonist):
A patient receives naloxone after an opioid overdose. The nurse understands that naloxone is
effective because it is a:
A) Full agonist at mu-opioid receptors
B) Competitive antagonist at mu-opioid receptors
C) Partial agonist at mu-opioid receptors
D) Non-competitive antagonist at mu-opioid receptors
[CORRECT] B
Pharmacology Guide ACTUAL EXAM
2026/2027 | Principles of Pharmacology
Guide | Verified Q&A | Pass Guaranteed -
A+ Graded
ART A – MULTIPLE CHOICE (Q1–60)
P
Q1 (Pharmacokinetics – first-pass effect):
A nurse is teaching a patient about why oral morphine requires a higher dose than intravenous
morphine. Which statement by the nurse best explains the first-pass effect?
A) "The liver metabolizes a portion of the drug before it reaches systemic circulation."
B) "The kidneys filter out most of the drug before it can act on receptors in the brain."
C) "The stomach acid destroys approximately 50% of the drug before absorption occurs."
D) "The blood-brain barrier prevents oral drugs from entering the central nervous system."
[CORRECT] A
Rationale: The first-pass effect refers to hepatic metabolism of a drug after absorption from the
GI tract but before reaching systemic circulation, which significantly reduces bioavailability of
orally administered drugs like morphine. Option B is incorrect because renal filtration occurs
after systemic circulation, not before. Option C is incorrect because stomach acid does not
destroy 50% of morphine; the liver is responsible for first-pass metabolism. Option D is incorrect
because the blood-brain barrier affects CNS entry after systemic circulation, not oral
bioavailability.
Q2 (Pharmacokinetics – factors affecting absorption):
A patient with chronic heart failure is prescribed furosemide. The nurse knows that which factor
will most likely DECREASE the rate of oral drug absorption in this patient?
A) Increased gastric motility
B) Decreased splanchnic blood flow
C) Increased surface area of the small intestine
D) Alkaline urine pH
[CORRECT] B
Rationale: In heart failure, decreased cardiac output reduces splanchnic (intestinal) blood flow,
which slows the rate of drug absorption from the GI tract because less blood is available to carry
absorbed drug into systemic circulation. Option A is incorrect because increased gastric motility
would actually decrease absorption time, not decrease the rate. Option C is incorrect because
increased surface area enhances, not decreases, absorption. Option D is incorrect because
urine pH affects renal elimination, not GI absorption.
, 3 (Pharmacokinetics – protein binding):
Q
A 78-year-old patient with low serum albumin is prescribed warfarin. The nurse should monitor
closely for which potential effect?
A) Decreased drug efficacy due to reduced plasma concentration
B) Increased risk of bleeding due to higher free (unbound) drug concentration
C) Increased protein binding causing drug accumulation in tissues
D) Decreased volume of distribution leading to subtherapeutic levels
[CORRECT] B
Rationale: Warfarin is highly protein-bound (approximately 99%); when albumin is low, less drug
is bound to protein, leaving more free (unbound, pharmacologically active) drug available to
exert anticoagulant effects and increasing bleeding risk. Option A is incorrect because free drug
concentration increases, not decreases. Option C is incorrect because low albumin decreases,
not increases, protein binding. Option D is incorrect because volume of distribution is not the
primary concern; the concern is increased free fraction and toxicity.
Q4 (Pharmacokinetics – half-life):
A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A) 6 hours
B) 12 hours
C) 24 hours
D) 30 hours
[CORRECT] D
Rationale: Steady-state concentration is typically reached after approximately 5 half-lives; with a
6-hour half-life, 5 × 6 = 30 hours. Option A represents one half-life (50% of steady state). Option
B represents two half-lives (75% of steady state). Option C represents four half-lives (94% of
steady state). Clinical practice accepts 5 half-lives as the time to reach steady state.
Q5 (Pharmacokinetics – CYP450):
The nurse is reviewing a patient's medication list and notes that the patient takes simvastatin
and recently started taking clarithromycin. What is the nurse's primary concern?
A) Clarithromycin inhibits CYP3A4, increasing simvastatin levels and risk of rhabdomyolysis
B) Clarithromycin induces CYP3A4, decreasing simvastatin effectiveness
C) Simvastatin inhibits clarithromycin metabolism, causing antibiotic toxicity
D) The combination causes additive hypotension
[CORRECT] A
Rationale: Clarithromycin is a potent CYP3A4 inhibitor; simvastatin is a CYP3A4 substrate.
Inhibition increases simvastatin plasma levels, raising the risk of myopathy and rhabdomyolysis,
a potentially fatal muscle breakdown. Option B is incorrect because clarithromycin inhibits, not
induces, CYP3A4. Option C is incorrect because simvastatin does not inhibit clarithromycin
metabolism. Option D is incorrect because neither drug significantly affects blood pressure.
Q6 (Pharmacokinetics – renal elimination):
A patient with chronic kidney disease (GFR 25 mL/min) is prescribed a drug that is 90%
eliminated unchanged by the kidneys. What is the nurse's priority action?
A) Administer the drug with food to enhance absorption
B) Recommend an increased dose to compensate for reduced elimination
, ) Notify the prescriber to discuss dose reduction or extended dosing interval
C
D) Monitor liver function tests because renal impairment increases hepatic metabolism
[CORRECT] C
Rationale: For drugs primarily eliminated by the kidneys, significantly reduced GFR (normal >90
mL/min) causes drug accumulation and toxicity; the nurse must notify the prescriber to adjust
the dose or extend the dosing interval based on renal function. Option A is incorrect because
absorption is not the issue; elimination is. Option B is incorrect because increasing the dose
would worsen accumulation and toxicity. Option D is incorrect because while some hepatic
compensation may occur, it is insufficient to prevent toxicity of a 90% renally eliminated drug.
Q7 (Pharmacokinetics – volume of distribution):
A drug has a very large volume of distribution (Vd > 200 L). What does this indicate to the
nurse?
A) The drug is highly concentrated in the plasma and will have a short duration of action.
B) The drug is extensively distributed into tissues and may have a prolonged effect.
C) The drug is rapidly metabolized by the liver and requires frequent dosing.
D) The drug is poorly absorbed from the gastrointestinal tract.
[CORRECT] B
Rationale: A large volume of distribution indicates extensive tissue distribution beyond plasma
volume (which is approximately 3 L for a 70 kg adult); drugs with large Vd (e.g., digoxin,
antidepressants) sequester in tissues and may have prolonged effects and half-lives. Option A
is incorrect because large Vd means low plasma concentration, not high. Option C is incorrect
because metabolism rate is independent of Vd. Option D is incorrect because absorption and
distribution are separate pharmacokinetic processes.
Q8 (Pharmacokinetics – blood-brain barrier):
Which characteristic allows a drug to most easily cross the blood-brain barrier?
A) High molecular weight and hydrophilic properties
B) Low lipid solubility and protein binding
C) Small molecular size and high lipid solubility
D) High degree of ionization at physiological pH
[CORRECT] C
Rationale: The blood-brain barrier consists of tight endothelial junctions that restrict passage of
large, polar, or ionized molecules; small, lipid-soluble (lipophilic), non-ionized drugs cross most
easily by passive diffusion. Option A is incorrect because large, hydrophilic molecules cannot
cross. Option B is incorrect because low lipid solubility prevents barrier penetration. Option D is
incorrect because ionized forms are water-soluble and cannot cross lipid membranes.
Q9 (Pharmacodynamics – agonist vs. antagonist):
A patient receives naloxone after an opioid overdose. The nurse understands that naloxone is
effective because it is a:
A) Full agonist at mu-opioid receptors
B) Competitive antagonist at mu-opioid receptors
C) Partial agonist at mu-opioid receptors
D) Non-competitive antagonist at mu-opioid receptors
[CORRECT] B
